NOVO B Stock Overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
Novo Nordisk Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.738.60|
|52 Week High||kr.834.50|
|52 Week Low||kr.475.45|
|1 Month Change||-5.08%|
|3 Month Change||14.89%|
|1 Year Change||51.28%|
|3 Year Change||134.70%|
|5 Year Change||162.47%|
|Change since IPO||13,603.16%|
Recent News & Updates
If You Like EPS Growth Then Check Out Novo Nordisk (CPH:NOVO B) Before It's Too Late
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|NOVO B||DK Pharmaceuticals||DK Market|
Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: NOVO B exceeded the Danish Market which returned 0.8% over the past year.
|NOVO B volatility|
|NOVO B Average Weekly Movement||4.3%|
|Pharmaceuticals Industry Average Movement||6.4%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DK Market||10.8%|
|10% least volatile stocks in DK Market||3.8%|
Stable Share Price: NOVO B is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: NOVO B's weekly volatility (4%) has been stable over the past year.
About the Company
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Novo Nordisk Fundamentals Summary
|NOVO B fundamental statistics|
Is NOVO B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NOVO B income statement (TTM)|
|Cost of Revenue||kr.24.76b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 04, 2022
|Earnings per share (EPS)||21.73|
|Net Profit Margin||33.11%|
How did NOVO B perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Is Novo Nordisk undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NOVO B (DKK738.6) is trading below our estimate of fair value (DKK1109.65)
Significantly Below Fair Value: NOVO B is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NOVO B is poor value based on its Price-To-Earnings Ratio (34x) compared to the European Pharmaceuticals industry average (20.3x).
PE vs Market: NOVO B is poor value based on its Price-To-Earnings Ratio (34x) compared to the Danish market (13.5x).
Price to Earnings Growth Ratio
PEG Ratio: NOVO B is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: NOVO B is overvalued based on its Price-To-Book Ratio (25.2x) compared to the XE Pharmaceuticals industry average (2.5x).
How is Novo Nordisk forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NOVO B's forecast earnings growth (13.6% per year) is above the savings rate (0.09%).
Earnings vs Market: NOVO B's earnings (13.6% per year) are forecast to grow faster than the Danish market (8.9% per year).
High Growth Earnings: NOVO B's earnings are forecast to grow, but not significantly.
Revenue vs Market: NOVO B's revenue (10.8% per year) is forecast to grow faster than the Danish market (6% per year).
High Growth Revenue: NOVO B's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NOVO B's Return on Equity is forecast to be very high in 3 years time (77.1%).
How has Novo Nordisk performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NOVO B has high quality earnings.
Growing Profit Margin: NOVO B's current net profit margins (33.1%) are lower than last year (33.8%).
Past Earnings Growth Analysis
Earnings Trend: NOVO B's earnings have grown by 4.6% per year over the past 5 years.
Accelerating Growth: NOVO B's earnings growth over the past year (15.1%) exceeds its 5-year average (4.6% per year).
Earnings vs Industry: NOVO B earnings growth over the past year (15.1%) exceeded the Pharmaceuticals industry 14.9%.
Return on Equity
High ROE: NOVO B's Return on Equity (74.1%) is considered outstanding.
How is Novo Nordisk's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NOVO B's short term assets (DKK86.5B) do not cover its short term liabilities (DKK95.6B).
Long Term Liabilities: NOVO B's short term assets (DKK86.5B) exceed its long term liabilities (DKK35.0B).
Debt to Equity History and Analysis
Debt Level: NOVO B's net debt to equity ratio (8%) is considered satisfactory.
Reducing Debt: NOVO B's debt to equity ratio has increased from 1.5% to 38.3% over the past 5 years.
Debt Coverage: NOVO B's debt is well covered by operating cash flow (264.3%).
Interest Coverage: NOVO B's interest payments on its debt are well covered by EBIT (97.1x coverage).
What is Novo Nordisk current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NOVO B's dividend (1.41%) is higher than the bottom 25% of dividend payers in the Danish market (1.39%).
High Dividend: NOVO B's dividend (1.41%) is low compared to the top 25% of dividend payers in the Danish market (6.21%).
Stability and Growth of Payments
Stable Dividend: NOVO B's dividend payments have been volatile in the past 10 years.
Growing Dividend: NOVO B's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (48.2%), NOVO B's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (39.6%), NOVO B's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lars Jorgensen (55 yo)
Mr. Lars Fruergaard Jorgensen has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member of Management Board. He served as Deputy Chair of the Supervisory...
CEO Compensation Analysis
Compensation vs Market: Lars's total compensation ($USD8.11M) is above average for companies of similar size in the Danish market ($USD3.33M).
Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.
Experienced Management: NOVO B's management team is considered experienced (3.5 years average tenure).
Experienced Board: NOVO B's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Novo Nordisk A/S's employee growth, exchange listings and data sources
- Name: Novo Nordisk A/S
- Ticker: NOVO B
- Exchange: CPSE
- Founded: 1923
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.1.696t
- Shares outstanding: 2.27b
- Website: https://www.novonordisk.com
Number of Employees
- Novo Nordisk A/S
- Novo Allé 1
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.